# A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

> **NCT03138499** · PHASE3 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 23 (actual)

## Conditions studied

- Hodgkin's Disease

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Brentuximab vedotin

## Key facts

- **NCT ID:** NCT03138499
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-26
- **Primary completion:** 2021-02-22
- **Final completion:** 2021-02-22
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Insufficient enrollment.
- **Last updated:** 2024-01-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03138499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03138499, "A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03138499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*